Skip to main content

Table 1 Histiocytic and reticulum cell neoplasia: overview

From: Inflammatory pseudotumor-like follicular dendritic cell tumor: an underdiagnosed neoplasia

  Immunohistochemical profile Clinical course
Langerhans cell histocytosis and CD1a+; S100 protein+; CD68−/+; lisozime-; CD21/CD35-; EBV-1 [Birbeck granules+] Variable clinical presentation: localized indolent to systemic aggressive
Langerhans cell sarcoma Agressive
Indeterminate dendritic cell tumor CD1a+; CD4+; Fascin+; S100+; CD68+/−; langerin [Birbeck granules–]- Most frequently localized
Interdigitating reticulum cell tumor Positive: S100 protein, fascin; Frequently positive: CD4, CD11c, CD14, CD45, CD68, HLA-DR, lisozime, EMA; Negative: CD1a, langerin, CD21/CD35, CD23 Mostly lymph nodes; very aggressive
Follicular dendritic cell tumor Positive: CD21/CD35, CD23, KiM4p, CNA42, clusterin, D2.40 (membrane), desmoplakin, fascin, EGFR, HLA-DR;
Sometimes positive: CD4, CD11a, CD14, CD20, CD45, CD68, EMA, S100 protein, smooth muscle actin; IPT-like cases consistently EBV+; Negative: CD1a, CD3, CD34, CD79a, myeloperoxidase, lisozime, HMB45
Mostly lymph nodes; middle age around the 5th decade; one third extranodal; moderately aggressive.
IPT-like cases mostly liver and spleen, female patients, more indolent course.
Fibroblastic reticular cell tumor / CIRC (cytokeratin positive interstitial reticular cell) tumor2 Positive: Vimentin; CIRC: cytokeratins, EMA, CD21, fascin; Frequently positive: smooth muscle actin, desmin, factor XIIIa; Negative: CD35, D2.40, CD1a, S100, EBV Indolent (localized cases) to aggressive
Histiocytic sarcoma Positive: CD68, CD163, CD4, CD11c, CD14, lysozyme; Negative: B and T cell markers, CD30, EMA, CD21, CD23, CD35, CD1a, langerin/CD207, CD13, CD33, myeloperoxidase, cytokeratins, HMB45; S100 protein positive in 50% cases Frequently extranodal;
Mostly aggressive
  1. Based on References [4,5,6,7,8,9,10]; 1: see Reference [5]; 2: see Reference [8]